Podcast: Ensuring Reliable Quality in Excipient Products

Shawn Branning, Global Strategic Marketing Manager at IFF – Pharma Solutions

Former FDA Commissioner lays out roadmap for building out excess capacity to deal with pandemic situations

This session was originally broadcast as part of the CPHI Worldwide 2021 digital content programme. Developing medicines for the pediatric population can be challenging, requiring different formulations, dosage forms and strengths, or different routes of administration. This session explores the hurdles and emerging opportunities to develop an optimal drug delivery addressing issues such as adherence and acceptability in the pediatric population. Critical development & administration challenges for paediatric medicines New technologies for developing and delivering optimal dosage forms Advantages and Disadvantages of Standards and Novel Strategies for Drug Administration in Paediatrics Emerging Opportunities

For nearly 60 years, Avicel®️ has exceeded the performance of common pill binders by pushing the boundaries of science in tablet binding, leading to a premier product supported by true experts in the field. Find out more.

Meet the makers of Avicel®️ and METHOCEL™️. Delivering expertise, innovation, and a passion to solve for drug delivery. Find out more

Our experts can help you design an optimal liquid or semi-solid application using our broad portfolio of specialized excipients and deep expertise in suspensions. Find out more.

With decades of vital experience in the pharma industry, we have a proven track record of working with customers around the globe to differentiate drug formulations and solve the toughest challenges with our robust excipients portfolio. Find out more.

The changing landscape for coverage of healthcare services and medical products is creating new challenges in making sure patients have affordable access to care, and that those financing these opportunities can sustain these investments. How we can develop sustainable models for covering the cost of new innovations and modernize our payment models; to make sure that patients have access to the medical care they need without bankrupting our healthcare system. What are the new models for healthcare delivery that we’ll need to embrace? CPHI is delighted to welcome, Dr. Scott Gottlieb, who served as the 23rd Commissioner of Food and Drugs, for our regulatory keynote. Aired as part of the CPHI Festival of pharma

The changing landscape for coverage of healthcare services and medical products is creating new challenges in making sure patients have affordable access to care, and that those financing these opportunities can sustain these investments. How we can develop sustainable models for covering the cost of new innovations and modernize our payment models; to make sure that patients have access to the medical care they need without bankrupting our healthcare system. What are the new models for healthcare delivery that we’ll need to embrace? CPHI is delighted to welcome, Dr. Scott Gottlieb, who served as the 23rd Commissioner of Food and Drugs, for our regulatory keynote. Aired as part of the CPHI Festival of pharma

Direct compression could simplify production of hydrophilic matrix tablets, but this method historically has often been challenging due to poor flow properties and low compressibility of powder blends —until now. This whitepaper will reveal how DuPont Nutrition & Biosciences’ unique portfolio and deep expertise can provide several options to make effective production of hydrophilic matrix tablets more convenient and cost-effective than ever.

At DuPont Nutrition & Biosciences (N&B) we understand dietary supplements. Backed by decades of expertise and a vast portfolio of solutions, we collaborate with you to turn your ideas into shelf-ready products in a variety of dosage forms. Whether you’re searching for clean label, plant-based and consumer-friendly capsules, great tasting gummies or creating smaller tablets for consumer convenience, we’re here to help every step of the way.

DuPont Pharma Solutions draws from the rich experience and expertise of historically market-leading excipient companies who pioneered brands like Avicel®️, the first pharma tablet binder, METHOCEL™️, a leading brand across multiple applications, Ac-Di-Sol®️, a superdisintegrant, and POLYOX®️, a thermoplastic solution with varied functionality. Our pharma-dedicated global research facilities and a wide manufacturing network locate us close to our customers. This short video summarizes the value proposition we offer to our customers.

We have the excipients and APIs that can help you meet your formulation needs. When you need a pharmaceutical solution and the technical expertise to put it to work quickly in your formulation, there are more reasons than ever to rely on us. Our products comply with the requirements of Food and Drug Administration (FDA), Food Chemicals Codex, Codex Alimentarius, United States Pharmacopeia (USP), National Formulary (NF), Japanese Pharmacopoeia, European Pharmacopoeia and British Pharmacopoeia. In addition, they can meet most requirements of Chinese Pharmacopoeia.

Do you know that ETHOCEL™ Premium Polymers are an excellent choice for modified release applications in pharmaceuticals? Available in many viscosity grades with high purity, this range of water-insoluble polymers is essentially tasteless, colorless, odorless, and very inert physiologically. As a water insoluble film-forming material, ETHOCEL™ polymers are useful for taste masking pharmaceutical active ingredients in addition to forming controlled release coatings for multiparticulates or providing an additional moisture barrier for water sensitive ingredients.

Do you know that METHOCEL™ is one product that can do it all – and has been in continuous production for over seven decades? Pharmaceutical companies are continuously looking for ways to innovate – through new technologies such as controlled release systems and oral films, or through faster and more efficient manufacturing processes. METHOCEL™ Premium family of products offers exceptional flexibility and a broad range of properties typically not found in other water-soluble polymers.

A versatile excipient addressing your critical formulation needs
Functionalities tailored to requirements of dosage form, formulation and technology. With the development of differentiated grades, Avicel® remains an indispensable formulation tool, boosting productivity and meeting tough formulation challenges. 


Contact DuPont for assistance with choosing the optimal Avicel® grade or for help with your tableting formulation issues.

Because Health Matters
At DuPont, we aim to help our pharma customers overcome everyday challenges and innovate future solutions. Armed with essential excipients and vital expertise, our broad portfolio is designed to deliver performance and cost advantages in various oral solid dosage forms. Couple that with leading QbD programs, regulatory expertise and a wide network of global problem solving experts, we can help deliver a consistent, high-quality offering, at the right time, every time.

Treatment for GERD (gastroesophageal reflux disease) is generally targeted for gastric acid neutralization and suppression of gastric acid production and/or secretion. However, another key approach to alleviate the condition is minimizing the exposure of the esophagus to acidic refluxate via raft-forming anti-reflux preparation wherein a viscous gel forms a physical barrier above the stomach contents and prevents it from refluxing back into the esophagus. This whitepaper from DuPont provides key insights into how sodium alginate acts as the key functional ingredient in anti-reflux formulations but also how the combined functionality of all ingredients creates the raft forming function via optimum concentration in formulation.